echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA oncology: "God medicine" aspirin again, age is very elegant?

    JAMA oncology: "God medicine" aspirin again, age is very elegant?

    • Last Update: 2021-01-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Colorectal cancer is one of the three most common cancers in the world, with the second highest number of deaths among cancer types, according to the Global Cancer Burden Report 2020.
    , the incidence and mortality of colorectal cancer are also on the rise, and most patients are found to be in the middle and late stages.
    for people at high risk of colorectal cancer, colonoscopy to see if the colon wall has a veneer (adenoma) growth, is a common means of disease surveillance.
    but colonoscopy is not unmissable, and there are still a significant number of patients who may develop colorectal cancer, especially right (near end) colon cancer.
    As early as 2018, published in the Lancet, a multidisciplinary collaboration between the University of Leeds, the University of Nottingham, the University of Bradford and the University of Newcastle, called seAFOod, confirmed that aspirin and purified omega-3 can reduce the amount of precancerote polyps in patients at high risk of colorectal cancer and are expected to lead to additional prevention on the basis of colonoscopy.
    , the conclusion that aspirin prevents colorectal cancer has been repeatedly argued.
    For example, a CAPP2 study, also published in Lancet last June, found that taking aspirin in early adulthood (average age 45) halved the risk of colorectal cancer in high-risk populations with genetic predispositions, and that the prevention effect lasted for up to 10-20 years! For this reason, the role of aspirin in preventing colorectal cancer has been recommended by several guidelines.
    , however, there have been few reports of a link between colorectal cancer risk in older groups, especially those over 70, and aspirin prevention medications.
    study, led by harvard medical school scholars, supplemented this with evidence and published in the latest journal JAMA oncology.
    researchers analyzed data from two large-scale u.S. queue studies, the Nurses' Health Study (1980.06.01-2014.06.30) and the Health Professional Follow-up Study (1986.01.01-2014.01.31).
    included 94,540 participants aged 70 and over.
    the Multivariate Adjusted Colorectal Cancer Risk Ratio (HR) and 95% CIs using the Cox Proportional Risk Model.
    94,540 participants aged 70 or over (average age, 76.4 years for women and 77.7 years for men);
    , a total of 1431 cases of colorectal cancer were recorded during follow-up.
    other risk factors, regular use of aspirin significantly reduced the risk of colorectal cancer after age 70 (HR-0.80; 95% CI, 0.72-0.90) compared to irregular use.
    , however, further analysis showed that the above protective effects could only be observed in people who had started using aspirin before the age of 70 (HR=0.80; 95% CI, 0.67-0.95).
    , although starting aspirin after age 70 reduced the risk of colorectal cancer by 8%, the difference was meaningless (HR-0.92; 95% CI, 0.76-1.11).
    researchers also point out that while both team studies were conducted among trained health care professionals, post-mortem observational studies still have limitations.
    , it is still necessary to further clarify the biological mechanisms of aspirin in people of different ages in the future.
    these studies, aspirin prevents colorectal cancer or is effective and affected by the age at which the drug is used.
    , several international guidelines have recommended that patients with Lynch syndrome, a hereditary non-polypic colorectal cancer, consider taking aspirin to prevent colorectal cancer.
    but medication is no small matter, anyone should consult a doctor before taking aspirin for a long time.
    : Guo CG, et al. Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021 Jan 21. doi: 10.1001/jamaoncol.2020.7338.MedSci Original Source: MedSci Original Copyright Notice: All notes on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medicine, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.